Clinical Endocrinology (1991) 34, 535–540

Author index to Volume 34

Abdulla A.F. see Davies S.C.
Aiken B. see Whitehead H.M.
Åkerström G. see Joborn C.
Al-Othman S. see Holly J.M.P.
Aliffi A. see Calogero A.E.
Alsina M. see Ferrer J.P.
Ang V.T.Y. see Nussey S.S.
Anyaoku V. see Dornhorst A.
Atkinson A.B. Current therapy: The treatment of Cushing's syndrome 507
Atkinson A.B. see McKnight J.A.
Audi L. see Martinez-Mora J.

Bangah M.L. see Kettel L.M.
Barbieri R.L. see Ziegler T.R.
Barry-Walsh C. see Fenton A.J.
Bearcroft C.P., Toms G.C., Williams S.J., Noonan K. & Monson J.P. Thyroxine replacement in post-radioiodine hypothyroidism 115
Beard R.W. see Dornhorst A.
Benn J.J. see Bowes S.B.
Besser G.M. see Cunah D.
Besser G.M. see Kirk J.M.W.
Besser G.M. see Trainer P.J.
Besser G.M. see Tsagarakis S.
Bhagat C.I. see Fenton A.J.
Bombi J.A. see Ferrer J.P.
Bouchard P. see Couzinet B.
Bovicelli L. see Salardi S.
Bowes S.B., Benn J.J., Scobie I.N., Umpleby A.M., Lowy C. & Sönkesen P.H. Glucose metabolism in patients with Cushing's syndrome 311
Brain C.E. see Suri D.
Brickell P.M. see Mullis P.E.
Brook C.G.D. see Mullis P.E.
Brook C.G.D. see Saini S.
Brook C.G.D. see Suri D.
Bryden M.P. see Imperato-McGinley J.
Buccianti G. see Cantalamessa L.
Buchanan C.R. see Rutherford O.M.
Burger H.G. see Kettel L.M.
Burnett A.K. see Wilson R.
Burns F. see Wilson R.
Byfield P.G.H. see Worthington J.
Byrne J. see Nussey S.S.

Cacciari E. see Salardi S.
Calogero A.E., Fornito M.C., Aliffi A., Vicari E., Moncada M.L., Mantero F., Polosa P. & D'Agata R. Role of peripherally infused angiotensin II on the human hypothalamic-pituitary-adrenal axis 183
Cantalamessa L., Cremagnani L., Orsatti A., Vigna L. & Buccianti G. Increased growth hormone response to growth hormone releasing hormone induced by erythropoietin in uraemic patients 85
Caron J. see Vistelle R.
Chanson P. see Duranteau L.
Chard T. see Davies S.C.
Chard T. see Holly J.M.P.
Chaufour-Higel B. see Vistelle R.
Chow C.C., Phillips D.I.W., Lazarus J.H. & Parkes A.B. Effect of low dose iodide supplementation on thyroid function in potentially susceptible subjects: are dietary iodide levels in Britain acceptable? 413
Christensen S.E. see Ørskov H.
Cicognani A. see Salardi S.
Clayton R.N. & Wass J.A.H. Editorial
Cohn D. see Tunny T.J.
Conget J.I. see Ferrer J.P.
Corcuff J.-B. see Tabarin A.
Corrigan E. see Fox R.
Cotterill A.M. see Davies S.C.
Cotterill A.M. see Holly J.M.P.
Couch R.M. see Moore P.S.J.
Coulson V.J. see Davies S.C.
Couzinet B., Lahlou N., Thomas G., Thalabard J.C., Bouchard P., Roger M. & Schaison G. Effects of gonadotrophin releasing hormone antagonist and agonist on the pulsatile release of gonadotrophins and α-subunit in postmenopausal women 477
Cremagnani L. see Cantalamessa L.
Crocket G.T. see Wilson R.
Crosby S.R. see Nussey S.S.
Cross K.W. see Parle J.V.
Croughs R.J.M. see Van't Verlaat J.W.
Crowne E.C. see Wallace W.H.B.
Cunnah D. & Besser G.M. Current therapy: Management of prolactinomas 231

D'Agata R. see Calogero A.E.
D'Urso R. see Falaschi P.
Daisuke Inoue, Kaoru Sato, Masahiro Maeda, Hidetoshi Inoko, Kimiyoshi Tsuji, Toru Mori & Hiroo Imura. Genetic differences shown by HLA typing among Japanese patients with euthyroid Graves' ophthalmopathy, Graves' disease and Hashimoto's thyroiditis: genetic characteristics of euthyroid Graves' ophthalmopathy 57
Davies M. see Dornhorst A.
Davies S.C. see Kirk J.M.W.
Davies S.C., Holly J.M.P., Coulson V.J., Cotterill A.M., Abdulla A.F., Whittaker P.G., Chard T. & Wass

J.A.H. The presence of cation-dependent proteases for insulin-like growth factor binding proteins does not alter the size distribution of insulin-like growth factors in pregnancy 501
Davis A.D. Commentary: Thyroxine replacement therapy 103
Davis J.E. Commentary: Heterogeneity of growth hormone production in human pituitary tumour cells 3
Daykin J. see Franklyn J.A.
de Haan-Meulman M. see Tas M.
de Jong F.H. see Klijn J.G.M.
de Zegher F. see Massa G.
Delemer B. see Vistelle R.
Delisle B. see Vistelle R.
Dinan T. see O'Keane V.
Donati S. see Salardi S.
Dornhorst A., Davies M., Anyaoku V., Hampton S.M., Elkeles R.S., Beard R.W. & Johnston D.G. Abnormalities in fasting circulating proinsulin concentration in mild gestational diabetes 211
Drexhage H.A. see Tas M.
Drolc Z. see Franklyn J.A.
Duranteau L., Chanson P., Lavoinne A., Horlait S., Lubetzki J. & Kuhn J.M. Effect of the new dopaminergic agonist CV 205–502 on plasma levels and tumour size in bromocriptine-resistant prolactinomas 25

Ebeling P.R. see Shulkes A.
Edwards A.C. see Spector T.D.
Egozcue J. see Martinez-Mora J.
Eiji Ohmura see Naoya Emoto
Eisen V. see Ong A.C.M.
Elkeles R.S. see Dornhorst A.
Endo K. see Hatabu H.
Engelhardt D. see Luppa P.

Faglia G. Commentary: Should dopamine agonist treatment for prolactinomas be life-long? 173
Falaschi P., Rosa M., Rocco A., D'Urso R., Proietti A. & Melis G.B. Effects of ritanserin, specific 5HT-2 antagonist, on PRL secretion in normal subjects and in different hyperprolactinaemic conditions 449
Farmer M. see Franklyn J.A.
Fay R. see Vistelle R.
Feek C.M. see Ford H.C.
Fenton A.J., Gutteridge D.H., Kent G.N., Price R.I., Retallack R.W., Bhagat C.I., Worth G.K., Thompson R.I., Watson I.G., Barry-Walsh C. & Matz L.R. Intravenous aminobisphosphonate in Paget's disease: clinical, biochemical, histomorphometric and radiological responses 197
Ferrari-Baliviera E. see Ziegler T.R.
Ferrer J.P., Halperin I., Conget J.I., Alsina M., Martinez-Osaba M.J., Palou J., Bombi J.A. & Vilardell E. Primary localized cutaneous amyloidosis and familial medullary thyroid carcinoma 435
Fletcher D.R. see Shulkes A.
Ford H.C., Johnson L.A., Feek C.M. & Newton J.D. Iodine intake and the seasonal incidence of thyrotoxicosis in New Zealand 179
Fornito M.C. see Calogero A.E.
Fox R., Corrigan E., Thomas P.A. & Hull M.G.R. The diagnosis of polycystic ovaries in women with oligo-amenorrhoea: predictive power of endocrine tests 127
Franklyn J.A. Review: Syndromes of thyroid hormone resistance 237
Franklyn J.A. see Parle J.V.
Franklyn J.A., Daykin J., Drolc Z., Farmer M. & Sheppard M.C. Long-term follow-up treatment of thyrotoxicosis by three different methods 71
Frey C. see Schopohl J.
Froud A.L.J. see Kirk J.M.W.

Gajdusek D.C. see Imperato-McGinley J.
Gautier T. see Imperato-McGinley J.
Gibold C. see Vistelle R.
Gibson S. see Wallace W.H.B.
Gordon R.D. see Tunny T.J.
Grossman A. see Trainer P.J.
Grossman A. see Tsagarakis S.
Grulet H. see Vistelle R.
Guerin J. see Tabarin A.
Gutteridge D.H. see Fenton A.J.

Hadden D.R. see McKnight J.A.
Hadden D.R. see Whitehead H.M.
Hale P.J. see Krentz A.J.
Halperin I. see Ferrer J.P.
Hampton S.M. see Dornhorst A.
Harris A.G. see Ørskov H.
Hatabu H., Kasagi K., Iida Y., Nosaka T., Misaki T., Hidaka A., Tokuda Y., Endo K., Mori T., Lee K.A., Tsuboi K., Hatanaka M. & Konishi J. Induction of c-fos and c-myc mRNA expression by immunoglobulin G from patients with Graves' disease in thyrotrophin 349
Hatanaka M. see Hatabu H.
Heath D. Current therapy: The treatment of hypercalcaemia of malignancy 155
Heikkilä P. see Leinonen P.
Heslop K.E. see Krentz A.J.
Hidaka A. see Hatabu H.
Hidetoshi Inoko see Daisuke Inoue
Himsworth R.L. see Worthington J.

Hindmarsh P.C. see Mullis P.E.
Hindmarsh P.C. see Saini S.
Hindmarsh P.C. see Suri D.
Hiroo Imura see Daisuke Inoue
Hiroshi Demura see Naoya Emoto
Hofland L.J., Velkeniers B., Van Koetsveld P.M., Hooghe-Peters E.L. & Lamberts S.W.J. The relationship between growth hormone (GH) messenger ribonucleic acid levels and hormone release from individual cells derived from human GH-secreting pituitary adenomas 5
Holly J.M.P. see Davies S.C.
Holly J.M.P., Cotterill A.M., Jemmott R.C., Shears D., Al-Othman S., Chard T. & Wass J.A.H. Inter-relations between growth hormone, insulin, insulin-like growth factor-I (IGF-I) and sex hormone-binding globulin in acromegaly 275
Homburg R. see Ong A.C.M.
Hooghe-Peters E.L. see Hofland L.J.
Horlait S. see Duranteau L.
Horrocks P.M. see Krentz A.J.
Huber R. see Schopohl J.
Hull M.G.R. see Fox R.

Iida Y. see Hatabu H.
Imperato-McGinley J., Miller M., Wilson J.D., Peterson R.E., Shackleton C. & Gajdusek D.C. A cluster of male pseudohermaphrodites with 5α-reductase deficiency in Papua New Guinea 293
Imperato-McGinley J., Pichardo M., Gautier T., Voyer D. & Bryden M.P. Cognitive abilities in androgen-insensitive subjects: comparison with control males and females from the same kindred 341
Isnard R. see Martinez-Mora J.

Jackson R. see Nussey S.S.
Jacobs H.S. see Ong A.C.M.
Jemmott R.C. see Holly J.M.P.
Jenkins C. see Wilson R.
Jenkins J.S. & Nussey S.S. Review: The role of oxytocin: present concepts 515
Jenkins J.S. see Nussey S.S.
Joborn C., Ljunghall S., Larsson K., Lindh E., Naessen T., Wide L., Akerstrom G. & Rastad J. Skeletal responsiveness to parathyroid hormone in healthy females: relationship to menopause and oestrogen replacement 335
Johnson L.A. see Ford H.C.
Johnston D.G. see Dornhorst A.
Johnston D.G. see Krentz A.J.
Jones A.E. see Tsagarakis S.
Jones D.A. see Rutherford O.M.
Jones J. see Saini S.
Jones S.C. see Parle J.V.

Kaal A. see Ørskov H.
Kabel P.J. see Tas M.
Kahri A. see Leinonen P.
Kaoru Sato see Daisuke Inoue
Kasagi K. see Hatabu H.
Kazo Shizume see Naoya Emoto
Keckstein J. see Rossmanith W.G.
Kennedy L. see McKnight J.A.
Kent G.N. see Fenton A.J.
Kettel L.M., Roseff S.J., Bangah M.L., Burger H.G. & Yen S.S.C. Circulating levels of inhibin in pregnant women at term: simultaneous disappearance with oestradiol and progesterone after delivery 19
Kimiyoshi Tsuji see Daisuke Inoue
Kirk J.M.W. see Trainer P.J.
Kirk J.M.W., Ross R.J.M., Trainer P.J., Froud A.L.J., Davies S.C., Savage M.O. & Besser G.M. Pyridostigmine fails to increase either spontaneous or GHRH-stimulated GH secretion during day or night in growth hormone-insufficient children 407
Klemm S.A. see Tunny T.J.
Klijn J.G.M., Van Geel B., de Jong F.H., Sandow J. & Krauss B. The relation between pharmacokinetics and endocrine effects of buserelin implants in patients with mastalgia 253
Konishi J. see Hatabu H.
Krauss B. see Klijn J.G.M.
Krentz A.J., Hale P.J., Horrocks P.M., Heslop K.E., Johnston D.G., Wright A.D. & Nattrass M. Metabolic effects of pharmacological adrenergic blockade in phaeochromocytoma 139
Kuhn J.M. see Duranteau L.

Lachelin G.C.L. see Ong A.C.M.
Lahlou N. see Couzinet B.
Lamberts S.W.J. see Hofland L.J.
Lang C.C., McMurray J.J., Moyses C. & Struthers A.D. Comparison of the effects of ANF 99–126 and ANF 103–126 of captopril-induced renin release in man 493
Larsson K. see Joborn C.
Lauritzen C. see Rossmanith W.G.
Lavoinne A. see Duranteau L.
Lazarus J.H. & Othman S. Review: Thyroid disease in relation to pregnancy 91
Lazarus J.H. see Chow C.C.
Lee K.A. see Hatabu H.
Leinonen P., Ranta T., Siegberg R., Pelkonen R., Heikkilä P. & Kahri A. Testosterone-secreting virilizing adrenal adenoma with human chorionic gonadotrophin receptors and 21-hydroxylase deficiency 31
Lemay A. & Lourdusmay M. Gonadotrophin releasing

hormone agonist suppressive treatment of ovarian function decreases serum LH-β and bioactive LH but maintains elevated levels of LH-α 191
Lewis S. see Whitehead H.M.
Lindh E. see Joborn C.
Littley M.D. see Wallace W.H.B.
Ljunghall S. see Joborn C.
Losa M. see Schopohl J.
Lourdusmay M. see Lemay A.
Lowy C. see Bowes S.B.
Lubetzki J. see Duranteau L.
Luppa P., Munker R., Nagel D., Weber M. & Engelhardt D. Serum androgens in intensive-care patients: correlations with clinical findings 305

Mandini M. see Salardi S.
Mantero F. see Calogero A.E.
Martin T.J. see Shulkes A.
Martinez-Mora J., Sáez J.M., Torán N., Isnard R., Pérez-Iribarne M.M., Egozcue J. & Audi L. Male pseudohermaphroditism due to Leydig cell agenesia and absence of testicular LH receptors 495
Martinez-Osaba M.J. see Ferrer J.P.
Masahiro Maeda see Daisuke Inoue
Massa G., de Zegher F. & Vanderschueren-Lodeweyckx M. Effect of growth hormone therapy on thyroid status of girls with Turner's syndrome 205
Matthews D.R. see Saini S.
Matthews D.R. see Suri D.
Matz L.R. see Fenton A.J.
McCance D.R. see McKnight J.A.
McGarrigle H.H. see Spector T.D.
McIlrath E. see McKnight J.A.
McKillop J.A. see Wilson R.
McKnight J.A., McCance D.R., Sheridan B., McIlrath E., Hadden D.R., Kennedy L. & Atkinson A.B. A long-term dose-response study of somatostatin analogue (SMS 201-995, octreotide) in resistant acromegaly 119
McLoughlin L. see Trainer P.J.
McMurray J.J. see Lang C.C.
Melis G.B. see Falaschi P.
Messinis I.E. & Templeton A. Attenuation of gonadotrophin release and reserve in superovulated women by gonadotrophin surge attenuating factor (GnSAF) 259
Miller M. see Imperato-McGinley J.
Misaki T. see Hatabu H.
Moncada M.L. see Calogero A.E.
Monson J.P. see Bearcroft C.P.
Moore C. see Wallace W.H.B.
Moore P.S.J., Couch R.M., Perry Y.S., Shuckett E.P. & Winter J.S.D. Allgrove syndrome: an autosomal recessive syndrome of ACTH insensitivity, achalasia and alacrima 107
Mori T. see Hatabu H.
Moyses C. see Lang C.C.
Muller O.A. see Schopohl J.
Mullis P.E., Patel M.S., Brickell P.M., Hindmarsh P.C. & Brook C.G.D. Growth characteristics and response to growth hormone therapy in patients with hypochondroplasia: genetic linkage of the insulin-like growth factor I gene at chromosome 12q23 to the disease in a subgroup of these patients 265
Munker R. see Luppa P.

Naessén T. see Joborn C.
Nagel D. see Luppa P.
Naoya Emoto, Eiji Ohmura, Osamu Isozaki, Toshio Tsushima, Kazo Shizume & Hiroshi Demura. Phorbol ester, not growth hormone releasing factor, consistently stimulates growth hormone release from somatotroph adenomas in culture 377
Nattrass M. see Krentz A.J.
Navarranne A. see Tabarin A.
Newton J.D. see Ford H.C.
Noonan K. see Bearcroft C.P.
Nosaka T. see Hatabu H.
Nussey S.S. see Jenkins J.S.
Nussey S.S., Page S.R., Peterson D.B., Byrne J., Crosby S.R., White A., Ang V.T.Y., Jackson R. & Jenkins J.S. Corticotrophin releasing hormone (CRH 1-41) stimulates the secretion of adrenocorticotrophin, vasopressin and oxytocin but not adrenocorticotrophin precursors: evidence from petrosal sinus sampling in man 51

O'Hanlon M. see O'Keane V.
O'Keane V., O'Hanlon M., Webb M. & Dinan T. *d*-Fenfluramine/prolactin response throughout the menstrual cycle: evidence for an oestrogen-induced alteration 289
Ong A.C.M., Eisen V., Rennie D.P., Homburg R., Lachelin G.C.L., Jacobs H.S. & Slater J.D.H. The pathogenesis of the ovarian hyperstimulation syndrome (OHS): a possible role for ovarian renin 43
Orsatti A. see Cantalamessa L.
Orsini L.F. see Salardi S.
Ørskov H., Christensen S.E., Weeke J., Kaal A. & Harris A.G. Effects of antibodies against octreotide in two patients with acromegaly 395
Osamu Isozaki see Naoya Emoto
Othman S. see Lazarus J.H.

Page S.R. see Nussey S.S.
Palou J. see Ferrer J.P.

Parkes A.B. see Chow C.C.
Parle J.V., Franklyn J.A., Cross K.W., Jones S.C. & Sheppard M.C. Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom 77
Parniex M. see Tabarin A.
Patel M.S. see Mullis P.E.
Pearson C. see Wilson R.
Pelkonen R. see Leinonen P.

Pérez-Iribarne M.M. see Martinez-Mora J.
Permanetter W. see Schopohl J.
Perry L. see Trainer P.J.
Perry L.A. see Spector T.D.
Perry Y.S. see Moore P.S.J.
Peterson D.B. see Nussey S.S.
Peterson R.E. see Imperato-McGinley J.
Phillips D.I.W. see Chow C.C.
Pichardo M. see Imperato-McGinley J.
Plowman P.N. see Tsagarakis S.
Polosa P. see Calogero A.E.
Preece M.A. see Rutherford O.M.
Preece M.A. see Saini S.
Price R.I. see Fenton A.J.
Pringle P.J. see Saini S.
Proietti A. see Falaschi P.

Ranta T. see Leinonen P.
Rastad J. see Joborn C.
Rees L.H. see Trainer P.J.
Rees L.H. see Tsagarakis S.
Rennie D.P. see Ong A.C.M.
Retallack R.W. see Fenton A.J.
Righetti F. see Salardi S.
Rocco A. see Falaschi P.
Roger M. see Couzinet B.
Roger P. see Tabarin A.
Rosa M. see Falaschi P.
Roseff S.J. see Kettel L.M.
Ross R.J.M. see Kirk J.M.W.
Rossmanith W.G., Keckstein J., Spatzier K. & Lauritzen C. The impact of ovarian laser surgery on the gonadotrophin secretion in women with polycystic ovarian disease 223
Round J.M. see Rutherford O.M.
Rubinstein C.A. see Shulkes A.
Rutherford O.M., Jones D.A., Round J.M., Buchanan C.R. & Preece M.A. Changes in skeletal muscle and body composition after discontinuation of growth hormone treatment in growth hormone deficient young adults 469

Sáez J.M. see Martinez-Mora J.
Saini S., Hindmarsh P.C., Matthews D.R., Pringle P.J., Jones J., Preece M.A. & Brook C.G.D. Reproducibility of 24-hour serum growth hormone profiles in man 455
Salardi S., Orsini L.F., Cacciari E., Righetti F., Donati S., Mandini M., Cicognani A. & Bovicelli L. Growth hormone, insulin-like growth factor I, insulin and C-peptide during human fetal life: in-utero study 187
Sandow J. see Klijn J.G.M.
Savage M.O. see Kirk J.M.W.
Schaison G. see Couzinet B.
Schopohl J., Losa M., Frey C., Wolfram G., Huber R., Permanetter W., von Pawel J., Muller O.A. & von Werder K. Plasma growth hormone (GH)-releasing hormone levels in patients with lung carcinoma 463
Scobie I.N. see Bowes S.B.
Shackleton C. see Imperato-McGinley J.
Shalet S.M. see Wallace W.H.B.
Shears D. see Holly J.M.P.
Sheppard M.C. see Franklyn J.A.
Sheppard M.C. see Parle J.V.
Sheridan B. see McKnight J.A.
Sheridan B. see Whitehead H.M.
Shuckett E.P. see Moore P.S.J.
Shulkes A., Fletcher D.R., Rubinstein C.A., Ebeling P.R. & Martin T.J. Production of calcitonin gene related peptide, calcitonin and PTH-related protein by a prostatic adenocarcinoma 387
Siegberg R. see Leinonen P.
Slater J.D.H. see Ong A.C.M.
Sönkesen P.H. see Bowes S.B.
Spatzier K. see Rossmanith W.G.
Spector T.D., Thompson P.W., Perry L.A., McGarrigle H.H. & Edwards A.C. The relationship between sex steroids and bone mineral content in women soon after the menopause 37
Struthers A.D. see Lang C.C.
Suri D., Hindmarsh P.C., Matthews D.R., Brain C.E. & Brook C.G.D. The pituitary gland is capable of responding to two successive doses of growth hormone releasing hormone (GHRH) 13

Tabarin A., Navarranne A., Guerin J., Corcuff J.-B., Parneix M. & Roger P. Use of ketoconazole in the treatment of Cushing's disease and ectopic ACTH syndrome 63
Tandon N., Zhang L. & Weetman A.P. HLA associations with Hashimoto's thyroiditis 383
Tas M., Kabel P.J., de Haan-Meulman M. & Drexhage H.A. Defects in monocyte polarization and dendritic cell clustering in patients with Graves'

disease. A putative role for a non-specific immunoregulatory factor related to retroviral p15E 441
Taylor R. Review: Insulin action 1991 159
Templeton A. see Messinis I.E.
Thakker R.V. Commentary: Molecular genetics of hypochondroplasia 249
Thalabard J.C. see Couzinet B.
Thomas G. see Couzinet B.
Thomas P.A. see Fox R.
Thompson P.W. see Spector T.D.
Thompson R.I. see Fenton A.J.
Thomson J.A. see Wilson R.
Tokuda Y. see Hatabu H.
Toms G.C. see Bearcroft C.P.
Torán N. see Martinez-Mora J.
Toru Mori see Daisuke Inoue
Toshio Tsushima see Naoya Emoto
Touzel R.J. see Trainer P.J.
Touzel R.J. see Tsagarakis S.
Trainer P.J. & Grossman A. Review: The diagnosis and differential diagnosis of Cushing's syndrome 317
Trainer P.J. see Kirk J.M.W.
Trainer P.J., Kirk J.M.W., McLoughlin L., Touzel R.J., Perry L., Rees L.H. & Besser G.M. The effects on anterior pituitary hormone secretion of salmon calcitonin in healthy volunteers 299
Tsagarakis S., Grossman A., Plowman P.N., Jones A.E., Touzel R.J., Rees L.H., Wass J.A.H. & Besser G.M. Megavoltage pituitary irradiation in the management of prolactinomas: long-term follow-up 399
Tsuboi K. see Hatabu H.
Tunny T.J., Gordon R.D., Klemm S.A. & Cohn D. Histological and biochemical distinctiveness of atypical aldosterone-producing adenomas responsive to upright posture and angiotensin 363

Umpleby A.M. see Bowes S.B.

Van Geel B. see Klijn J.G.M.
Van Koetsveld P.M. see Hofland L.J.
Van't Verlaat J.W. & Croughs R.J.M. Withdrawal of bromocriptine after long-term therapy of macroprolactinomas; effect on plasma prolactin and tumour size 175
Vanderschueren-Lodeweyckx M. see Massa G.
Velkeniers B. see Hofland L.J.
Vicari E. see Calogero A.E.
Vigna L. see Cantalamessa L.
Vilardell E. see Ferrer J.P.
Vistelle R., Grulet H., Gibold C., Chaufour-Higel B., Delemer B., Fay R., Delisle B. & Caron J. High permanent plasma adrenaline levels: a marker of adrenal medullary disease in medullary thyroid carcinoma 133
von Pawel J. see Schopohl J.
von Werder K. see Schopohl J.
Voyer D. see Imperato-McGinley J.

Wallace W.H.B., Crowne E.C., Shalet S.M., Moore C., Gibson S., Littley M.D. & White A. Episodic ACTH and cortisol secretion in normal children 215
Wass J.A.H. see Clayton R.N.
Wass J.A.H. see Davies S.C.
Wass J.A.H. see Holly J.M.P.
Wass J.A.H. see Tsagarakis S.
Watson I.G. see Fenton A.J.
Webb M. see O'Keane V.
Weber M. see Luppa P.
Weeke J. see Ørskov H.
Weetman A.P. see Tandon N.
White A. see Nussey S.S.
White A. see Wallace W.H.B.
Whitehead H.M., Aiken B., Lewis S., Sheridan B. & Hadden D.R. Physiological growth hormone secretion in adult growth hormone deficiency: comparison with normal controls 371
Whittaker P.G. see Davies S.C.
Wide L. see Joborn C.
Williams S.J. see Bearcroft C.P.
Wilmore D.W. see Ziegler T.R.
Wilson J.D. see Imperato-McGinley J.
Wilson R., McKillop J.H., Crocket G.T., Pearson C., Jenkins C., Burns F., Burnett A.K. & Thomson J.A. The effect of lithium therapy on parameters thought to be involved in the development of autoimmune thyroid disease 357
Winter J.S.D. see Moore P.S.J.
Wolfram G. see Schopohl J.
Worth G.K. see Fenton A.J.
Worthington J., Byfield P.G.H. & Himsworth R.L. Heterogeneity of circulating TSH-receptor antibodies in thyroid disease demonstrated directly by chromatography 147
Wright A.D. see Krentz A.J.

Yen S.S.C. see Kettel L.M.
Young L.S. see Ziegler T.R.

Zhang L. see Tandon N.
Ziegler T.R., Barbieri R.L., Young L.S., Wilmore D.W., Ferrari-Baliviera E. & Wilmore D.W. Effects of growth hormone admonistration on dehydroepiandrosterone sulphate, androstenedione, testosterone and cortisol metabolism during nutritional repletion 281

Clinical Endocrinology (1991) 34, 541–544

Subject index to Volume 34

Achalasia
in Allgrove syndrome 107
Acromegaly
dose–response study of octreotide in 119
GH, IGF-I, IGFBP-1 and SHBG in 275
effects of antibodies against octreotide 395
ACTH
secretion stimulated by corticotrophin releasing hormone 51
insensitivity in Allgrove syndrome 107
and cortisol secretion in children 215
secretion, effects of calcitonin 299
ACTH precursors
secretion not stimulated by corticotrophin releasing hormone 51
Adrenal adenoma
virilizing with hCG receptors and 21-hydroxylase deficiency 31
Adrenal medullary disease
in MTC, adrenaline levels a marker 133
Alacrima
in Allgrove syndrome 107
Aldosteronism
angiotensin II and posture 363
Allgrove syndrome
autosomal recessive syndrome of ACTH insensitivity, achalasia and alacrima 107
α-subunit
effect of GnRH agonist and antagonist on release in women 477
Aminobisphosphonate
in Paget's disease 197
Amyloidosis
cutaneous, and familial thyroid carcinoma 435
Androgens
in intensive-care patients 305
insensitive kindreds, cognitive abilities in 341
Androstenedione
effects of GH on in nutritional repletion 281
ANF
99–126 and 103–126, effects on captopril-induced renin release 493
Angiotensin II
and the hypothalamic–pituitary–adrenal axis 183
and aldosteronism 363
Autoimmune thyroid disease
and lithium therapy 357
AVP
secretion stimulated by corticotrophin releasing hormone 51
Bisphosphonates
in hypercalcaemia of malignancy (Current therapy) 155
Body composition
changes after GH discontinuation 469
Bone
mineral control and sex steroids after menopause 37
response to parathyroid hormone in women 335
Bromocriptine
for prolactinomas 173, 175
Buserelin
effects on LH in endometriosis 191
pharmacokinetics and endocrine effects in mastalgia 253

C-peptide
during fetal life 187
Calcitonin
in hypercalcaemia of malignancy (Current therapy) 155
salmon, effects on anterior pituitary hormone secretion 299
CGRP and PTHrP production by prostatic adenocarcinoma 387
Captopril
induced renin release, effects of ANF 99–126 and ANF 103–126 on 493
Children
effect of GH on thyroid in girls with Turner's syndrome 205
ACTH and cortisol secretion in 215
pyridostigmine and GH secretion in GH-deficient 407
biosynthetic GH treatment indications 417
Chromatography
of TRAb in Graves' disease 147
Cognitive abilities
in adrogen-insensitive kindreds 341
Corticosteroids
in hypercalcaemia of malignancy (Current therapy) 155
Corticotrophin releasing hormone
stimulates secretion of ACTH, AVP and oxytocin, but not ACTH precursors 51
Cortisol
and ACTH secretion in children 215
effects of GH on in nutritional repletion 281
Creuzfeldt-Jakob disease and hGH 527
Cushing's disease
ketoconazole in 63
Cushing's syndrome
glucose metabolism 311
diagnosis (Review) 317
current therapy 507

CV 205-502
effect on prolactin levels and tumour size in prolactinomas 25

Dendritic cells
clustering in Graves' disease 441
DHEAS
effect of GH on in nutritional repletion 281
Diabetes
gestational, proinsulin, glucose and insulin in 211

Ectopic ACTH syndrome
ketoconazole in 63
Endometriosis
effect of buserelin on LH 191
Erythropoietin
GH response to GHRH induced by, in uraemia 85
Eye
Graves' ophthalmopathy and HLA typing 57

d-Fenfluramine
PRL response in menstrual cycle: oestrogen-induced alteration 289
Fetus
inhibin production by 19
GH, IGF-I, insulin and C-peptide in blood of 187
FSH
effects of calcitonin on secretion 299

Genetics
of HLA types in Graves' ophthalmopathy, Graves' disease and Hashimoto's thyroiditis 51
Allgrove's syndrome 107
molecular, of hypochondroplasia 249, 265
male pseudohermaphrodites with 5α-reductase deficiency 293
cognitive abilities in androgen-insensitive kindreds 341
of HLA-DR in Hashimoto's thyroiditis 383
cutaneous amyloidosis and familial thyroid carcinoma 435
Geriatrics
abnormal TSH in the elderly 77
GH
production in pituitary tumour (Commentary) 3, 5
production, effects of successive GHRH on pituitary 13
response to GHRH induced by erythropoietin in uraemia 85
during fetal life 187
effect on thyroid of girls with Turner's syndrome 205
response in hypochondroplasia: genetics 249, 265
in acromegaly 275
effects on DHEAS, androstenedione, testosterol and cortisol in nutritional repletion 281
secretion, effect of calcitonin 299
secretion in adult GH deficiency 371
release from somatotroph adenomas stimulated by phorbol ester 377
secretion and pyridostigmine in GH-deficient children 407
biosynthetic GH treatment in children 417
24-hour serum profiles 455
levels with lung carcinoma 463
changes in skeletal muscle and body composition after discontinuation 469
and Creutzfeld-Jakob disease 533
GHRH
effects of successive doses on pituitary 13
Glucose metabolism
in Cushing's syndrome 311
GnSAF
effect on gonadotrophin in suprovulated women 259
Gonadotrophin
effects of GnSAF in superovulated women 259
effects of agonist and antagonist in women 477
Graves' disease
and HLA types 57
heterogeneity of TRAb by chromatography 147
induction of c-fos and c-myc mRNA by IgG from patients in FRTL5 349
defects in monocyte polarization and dendritic cell clustering in 441
Graves ophthalmopathy
and HLA types 57

Hashimoto's thyroiditis
and HLA types 57
HLA associations 383
HLA
types in euthyroid Graves' ophthalmopathy, Graves' disease and Hashimoto's thyroiditis 57
21-Hydroxylase deficiency
and virilizing adrenal adenoma 31
Hypercalcaemia of malignancy
(Current therapy) 155
Hyperprolactinaemia
effect of ritanserin on PRL secretion in 449
Hypochondroplasia
molecular genetics 249, 265
Hypothyroidism
treatment by thyroxine replacement (Commentary) 103, 115

Iodide
dietary, and thyroid function 413
^{131}I
treatment of thyrotoxicosis 71
and thyroxine replacement (Commentary) 103, 115

IGF
during fetal life 187
gene in hypochondroplasia 249, 265
in acromegaly 275
size distribution and proteases for IGFBP in pregnancy 501
IGFBP
in acromegaly 275
protease for, and IFG size distribution in pregnancy 501
Inhibin
levels in pregnant women and disappearance after delivery 19
Insulin
action (Review) 159
during fetal life 187
in gestational diabetes 211
Intensive-care patients
serum androgens in 305
Iodine
intake and seasonal incidence of thyrotoxicosis 179

Ketoconazole
in Cushing's disease and ectopic ACTH syndrome 63

Leydig cell agenesia
and male pseudohermaphroditism 477
LH
secretion, effect of calcitonin 299
receptors, absence, in male pseudohermaphroditism with Leydig cell agenesia 485
Lithium therapy
and autoimmune thyroid disease 357
Lung carcinoma
and plasma GH levels 463

Mastalgia
pharmacokinetics and endocrine effects of buserelin 253
Medullary thyroid carcinoma
plasma adrenaline marker of AMD 133
Men
pseudohermaphrodites with 5α-reductase deficiency 293
production of calcitonin, CGRP and PTHrP by prostatic adenocarcinoma 387
24-hour serum GH profiles 455
pseudohermaphroditism due to Leydig cell agenesia 485
effects of ANF 99–126 and ANF 103–126 on captopril-induced renin release in 493
MEN II
plasma adrenaline a marker 133
Monocytes
defects in polarization, and Graves' disease 441
Muscle
skeletal, changes after GH discontinuation 469

Nutritional repletion
effects of GH on DHEAS, androstenedione, testosterone and cortisol in 281

Octreotide
dose–response study in acromegaly 119
antibodies against, in acromegaly 395
Oestradiol
and inhibition disappearance after delivery 19
Oestrogen
relation to skeletal responsiveness to PTH in women 335
Ovarian hyperstimulation syndrome
pathogenesis: role for ovarian renin 43
Ovarian laser surgery
effect on gonadotrophin secretion in PCO 223
Ovarian renin
role in ovarian hyperstimulation syndrome 43
Oxytocin
secretion stimulated by corticotrophin releasing hormone 51
review 515
Oestrogen
effect on PRL response to *d*-fenfluramine in menstrual cycle 289

Paget's disease
response to aminobisphosphonate 197
Parathyroid hormone
effect on skeleton in women 335
PCO
diagnosis by endocrine tests 127
effect of ovarian laser surgery on gonadotrophin secretion 223
Phaeochromocytoma
plasma adrenaline a marker 133
metabolic effects of adrenergic blockade 139
Phenoxybenzamine
blockade in phaeochromocytoma 139
Phorbol ester
stimulates GH release from somatotroph adenomas 377
Pituitary
effect of successive GHRH on GH production 13
anterior, effects of calcitonin on hormone secretion 299
megavoltage irradiation in prolactinomas 399
Pituitary tumour
heterogeneity of GH production in (Commentary) 3, 5
Pregnancy
levels of inhibin in and disappearance after 19
thyroid disease in (Review) 91
proinsulin and insulin 211
proteases for IGFBP and IGF size distribution in 501

PRL
response to *d*-fenfluramine in menstrual cycle: oestrogen-induced alteration 289
secretion, effect of calcitonin 299
secretion, effect of ritanserin 449
Progesterone
and inhibin disappearance after delivery 19
Prolactinoma
effect of CV 205-502 25
use of bromocriptine 173, 175
management (Current therapy) 231
megavoltage irradiation 399
Propranolol
blockade in phaeochromocytoma 139
Prostatic adenocarcinoma
production of calcitonin, CGRP and PTHrP by 387
Proteases
for IGFBP and IGF size distribution in pregnancy 501
Protein kinase C
and GH and PRL secretion in somatotroph adenomas 377
Pseudohermaphroditism
male with 5α-reductase deficiency 293
male due to Leydig cell agenesia 485
Pyridostigmine
and GH secretion in GH-deficient children 407

5α-reductase deficiency
in male pseudohermaphrodites 293
Renin
effects of ANF 99–126 and ANF 103–126 on captopril-induced release 493
Ritanserin
effect of PRL secretion 449

Sex steroids
and bone mineral content soon after menopause 37
SHBG
in acromegaly 275
Sipple's syndrome
plasma adrenaline levels a marker 133

Testosterone
effects of GH on in nutritional repletion 281
Thyroid
disease in pregnancy (Review) 91
effect of GH on in girls with Turner's syndrome 205
autoimmune disease and lithium therapy 357
function and dietary iodide 413
familial carcinoma, and cutaneous amyloidosis 435
Thyroid hormone resistance
syndromes (Review) 237
Thyroidectomy
partial, in thyrotoxicosis 71
Thyroiditis
Hashimoto's, HLA types in 57
Hashimoto's, HLA associations 383
Thyrotoxicosis
long-term follow-up of treatment by ^{131}I or thyroidectomy 71
thyroxine replacement following radiodine (Commentary) 103, 115
iodine intake and seasonal incidence in New Zealand 179
Thyroxine replacement
in post-radiodine hypothyroidism (Commentary) 103, 115
TRAb
heterogeneity in Graves' disease, chromatography 147
TSH
abnormal in the elderly 77
secretion, effect of calcitonin 299
Turner's syndrome
effect of GH on thyroid of girls 205

Uraemia
GH response to GHRH induced by erythropoietin in 85

Women
levels of inhibin in pregnant and disappearance after delivery 19
virilizing adrenal adenoma with hCG receptors and 21-hydroxylase deficiency 31
sex steroids and bone mineral content after menopause 37
ovarian hyperstimulation syndrome, role of ovarian renin 43
thyroid disease in pregnancy (Review) 91
PCO with oligo-amenorrhoea, diagnosis by endocrine tests 127
effect of buserelin on LH in endometriosis 191
effect of GH on thyroid of girls with Turner's syndrome 205
proinsulin in gestational diabetes 211
effect of ovarian laser surgery on gonadotrophin secretion in PCO 223
buserelin in mastalgia 253
GnSAF in superovulated women 259
PRL response to *d*-fenfluramine in menstrual cycle: oestrogen induced alteration 289
effect of parathyroid hormone on skeleton of 335
megavoltage irradiation of prolactinomas 399
effect of GnRH antagonist and agonist in postmenopausal 477
proteases for IGFBP and IGF size distribution in pregnancy 501